Relay Therapeutics Inc

Relay Therapeutics CFO sells 972 shares at $14.79 to cover RSU taxes; the routine transaction shows modest insider activity and stability amid Phase III zovegalisib trials.

Relay Therapeutics CFO sells shares as part of a disciplined, rule‑based liquidity plan, signaling confidence amid strong regulatory progress and market gains.

Relay Therapeutics CFO’s 17,717‑share sale is a routine liquidity move, not a sign of distress – still bullish on the company’s oncology pipeline and FDA milestones.